Valuation Thermo Fisher Scientific, Inc.
Equities
TMO
US8835561023
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 572.28 USD | -1.14% |
|
-0.09% | +10.01% |
| Dec. 11 | Citigroup Upgrades Thermo Fisher Scientific to Buy From Neutral, Adjusts PT to $660 From $580 | MT |
| Dec. 08 | Why the Fed's Next Move Matters More Than Markets Admit |
Company Valuation: Thermo Fisher Scientific, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 184,605 | 262,925 | 216,998 | 205,083 | 198,988 | 215,010 | - | - |
| Change | - | 42.43% | -17.47% | -5.49% | -2.97% | 8.05% | - | - |
| Enterprise Value (EV) 1 | 196,015 | 293,318 | 242,962 | 231,923 | 226,254 | 243,296 | 238,972 | 233,174 |
| Change | - | 49.64% | -17.17% | -4.54% | -2.44% | 7.53% | -1.78% | -2.43% |
| P/E ratio | 29.2x | 34.3x | 31.2x | 34.4x | 31.5x | 32.1x | 28.9x | 25.2x |
| PBR | 5.39x | 6.45x | 4.89x | 4.39x | 4x | 4.12x | 3.78x | 3.46x |
| PEG | - | 1.6x | -3.32x | -2.8x | 4.51x | 4.02x | 2.6x | 1.7x |
| Capitalization / Revenue | 5.73x | 6.71x | 4.83x | 4.79x | 4.64x | 4.86x | 4.62x | 4.38x |
| EV / Revenue | 6.08x | 7.48x | 5.41x | 5.41x | 5.28x | 5.5x | 5.14x | 4.75x |
| EV / EBITDA | 19.2x | 22.6x | 20.3x | 21.3x | 20.8x | 21.8x | 19.9x | 18.3x |
| EV / EBIT | 20.5x | 24.2x | 22.1x | 23.6x | 23.3x | 24.1x | 22x | 19.9x |
| EV / FCF | 28.8x | 41.8x | 35x | 33.5x | 30.9x | 36.8x | 27.8x | 24.9x |
| FCF Yield | 3.48% | 2.39% | 2.85% | 2.99% | 3.24% | 2.72% | 3.59% | 4.02% |
| Dividend per Share 2 | 0.88 | 1.04 | 1.2 | 1.4 | 1.56 | 1.649 | 1.719 | 1.805 |
| Rate of return | 0.19% | 0.16% | 0.22% | 0.26% | 0.3% | 0.29% | 0.3% | 0.32% |
| EPS 2 | 15.96 | 19.46 | 17.63 | 15.45 | 16.53 | 17.85 | 19.8 | 22.73 |
| Distribution rate | 5.51% | 5.34% | 6.81% | 9.06% | 9.44% | 9.24% | 8.68% | 7.94% |
| Net sales 1 | 32,218 | 39,211 | 44,915 | 42,857 | 42,879 | 44,261 | 46,519 | 49,111 |
| EBITDA 1 | 10,214 | 12,969 | 11,971 | 10,878 | 10,863 | 11,169 | 12,001 | 12,713 |
| EBIT 1 | 9,556 | 12,138 | 10,985 | 9,810 | 9,707 | 10,083 | 10,839 | 11,702 |
| Net income 1 | 6,375 | 7,725 | 6,950 | 5,995 | 6,335 | 6,707 | 7,384 | 8,280 |
| Net Debt 1 | 11,410 | 30,393 | 25,964 | 26,840 | 27,266 | 28,286 | 23,962 | 18,164 |
| Reference price 2 | 465.78 | 667.24 | 550.69 | 530.79 | 520.23 | 572.28 | 572.28 | 572.28 |
| Nbr of stocks (in thousands) | 396,335 | 394,048 | 394,048 | 386,372 | 382,500 | 375,708 | - | - |
| Announcement Date | 2/1/21 | 2/2/22 | 2/1/23 | 1/31/24 | 1/30/25 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 32.06x | 5.5x | 21.78x | 0.29% | 215B | ||
| 71.91x | 18.86x | 44.03x | -.--% | 192B | ||
| 43.51x | 7.07x | 22.82x | 0.55% | 160B | ||
| 44.83x | 7.28x | 23.75x | -.--% | 137B | ||
| 20.73x | 2.48x | 12.06x | 2.31% | 57.67B | ||
| 36.61x | 7.45x | 24.66x | -.--% | 48.21B | ||
| 31.31x | 5.95x | 21.21x | 0.7% | 39.54B | ||
| 18.34x | 2.11x | 11.92x | 0.15% | 38.25B | ||
| 24.05x | 6.34x | 16.41x | 0.96% | 36.77B | ||
| 25.25x | 6.46x | 18.44x | 2.64% | 34.25B | ||
| Average | 34.86x | 6.95x | 21.71x | 0.76% | 95.91B | |
| Weighted average by Cap. | 42.20x | 8.56x | 25.52x | 0.46% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- TMO Stock
- Valuation Thermo Fisher Scientific, Inc.
Select your edition
All financial news and data tailored to specific country editions
















